



PRESS RELEASE

DANIOLABS

4th April 2005

DanioLabs Announce the Appointment of Dr David Chiswell as Non-Executive Chairman.

DanioLabs Ltd (Cambridge, UK), announced today the appointment of Dr David Chiswell as non-executive Chairman. Dr Chiswell replaces Dr Roger Brimblecombe who has retired from the DanioLabs Board. The Board wish to thank Dr Brimblecombe for all his help and guidance which he has given the company since its beginnings in 2002.

Dr Chiswell was a founder and CEO of Cambridge Antibody Technologies (CAT), one of the leading European Biotechnology companies. In addition to this new Chairmanship of DanioLabs Ltd, David is Chairman of Arrow Therapeutics, Sosei Co Ltd, the UK BioIndustry Association, a non-executive director of Arakis Ltd, and an advisor to private equity firms. This new appointment follows on from DanioLabs successful closing of a 1st round institutional investment of £3.2M in December 2004.

On his appointment to the board of DanioLabs, Dr Chiswell said,

"DanioLabs have already demonstrated that they have real potential to develop into a major biopharmaceutical company and I am delighted to have the opportunity to help them achieve this."

Notes to Editors:

DanioLabs (Cambridge, UK), is a drug discovery company that discovers and develops novel therapeutics primarily in neurological and ophthalmological diseases, with an expertise in the use of zebrafish as an model organism. In addition to identifying new pharmaceuticals for our own internal development, the Company also works with other companies applying the technologies to help them discover and develop their compounds.

DanioLabs develops validated disease models, and screen for phenotypic rescue from the disease state. This approach is used to identify novel uses for known drug compounds – drug reprofiling, or to validate and prioritize New Chemical Entities (NCEs) that have shown activity in *in-vitro* assays, and can be also be used in safety pharmacology assessment.

